New hope for Hard-to-Treat liver disease: steroid combo trial launches
NCT ID NCT06591468
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether adding prednisone to standard UDCA treatment helps people with primary biliary cholangitis (PBC) who also have moderate to severe interface hepatitis, a type of liver inflammation. About 244 adults will be randomly assigned to receive either UDCA alone or UDCA plus prednisone. The goal is to see if the combination improves liver test results and reduces symptoms like fatigue and itching.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
prednisone and ursodeoxycholic acid (UDCA)
What this could lead to
If successful, this could offer a new treatment option for PBC patients with interface hepatitis who currently have limited effective therapies.
What could go wrong
This is a mid-stage trial with 244 participants, so results may not apply to all patients. Prednisone has known side effects like weight gain and infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China
-
Xijing hospital
Xi'an, Shaanxi, 710032, China